These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 33319549)

  • 1. Heat shock protein 90α inhibitor, PU-H71 in combination with DHEA promoting apoptosis in triple-negative breast cancer cell line MDA-MB-231.
    Soudan H; Saeed H; Eldemellawy M; Shalaby M; Hassan M; Elkewedi M; El-Nikhely N
    Acta Biochim Pol; 2020 Dec; 67(4):561-570. PubMed ID: 33319549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.
    Gallerne C; Prola A; Lemaire C
    Biochim Biophys Acta; 2013 Jun; 1833(6):1356-66. PubMed ID: 23485394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prodigiosin/PU-H71 as a novel potential combined therapy for triple negative breast cancer (TNBC): preclinical insights.
    Anwar MM; Shalaby M; Embaby AM; Saeed H; Agwa MM; Hussein A
    Sci Rep; 2020 Sep; 10(1):14706. PubMed ID: 32895397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.
    Caldas-Lopes E; Cerchietti L; Ahn JH; Clement CC; Robles AI; Rodina A; Moulick K; Taldone T; Gozman A; Guo Y; Wu N; de Stanchina E; White J; Gross SS; Ma Y; Varticovski L; Melnick A; Chiosis G
    Proc Natl Acad Sci U S A; 2009 May; 106(20):8368-73. PubMed ID: 19416831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.
    Ambati SR; Lopes EC; Kosugi K; Mony U; Zehir A; Shah SK; Taldone T; Moreira AL; Meyers PA; Chiosis G; Moore MA
    Mol Oncol; 2014 Mar; 8(2):323-36. PubMed ID: 24388362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining.
    Lee Y; Li HK; Masaoka A; Sunada S; Hirakawa H; Fujimori A; Nickoloff JA; Okayasu R
    Radiother Oncol; 2016 Oct; 121(1):162-168. PubMed ID: 27666928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.
    Usmani SZ; Bona RD; Chiosis G; Li Z
    J Hematol Oncol; 2010 Oct; 3():40. PubMed ID: 20977755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
    Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
    Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy.
    Li HK; Matsumoto Y; Furusawa Y; Kamada T
    J Radiat Res; 2016 Sep; 57(5):572-575. PubMed ID: 27242340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PU-H71 effectively induces degradation of IκB kinase β in the presence of TNF-α.
    Qu Z; Wang S; Teng R; Yi X
    Mol Cell Biochem; 2014 Jan; 386(1-2):135-42. PubMed ID: 24114662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing therapeutic efficacy in breast cancer: a study on the combined cytotoxic effects of doxorubicin and MPC-3100.
    Gökşen Tosun N
    Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3249-3259. PubMed ID: 37917369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Debio-0932, a second generation oral Hsp90 inhibitor, induces apoptosis in MCF-7 and MDA-MB-231 cell lines.
    Özgür A; Kara A; Gökşen Tosun N; Tekin Ş; Gökçe İ
    Mol Biol Rep; 2021 Apr; 48(4):3439-3449. PubMed ID: 33999319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo.
    Hsieh YL; Tu HJ; Pan SL; Liou JP; Yang CR
    Biochim Biophys Acta Mol Cell Res; 2019 Jun; 1866(6):992-1003. PubMed ID: 30867138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators.
    Kale Ş; Korcum AF; Dündar E; Erin N
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Feb; 393(2):253-262. PubMed ID: 31522240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.
    Goldstein RL; Yang SN; Taldone T; Chang B; Gerecitano J; Elenitoba-Johnson K; Shaknovich R; Tam W; Leonard JP; Chiosis G; Cerchietti L; Melnick A
    J Clin Invest; 2015 Nov; 125(12):4559-71. PubMed ID: 26529251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic enhancement of apoptosis by coralyne and paclitaxel in combination on MDA-MB-231 a triple-negative breast cancer cell line.
    Kumari S; Mohan MG; Shailender G; Badana AK; Malla RR
    J Cell Biochem; 2019 Oct; 120(10):18104-18116. PubMed ID: 31172606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
    Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
    Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
    [No Abstract]   [Full Text] [Related]  

  • 18. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.
    Moulick K; Ahn JH; Zong H; Rodina A; Cerchietti L; Gomes DaGama EM; Caldas-Lopes E; Beebe K; Perna F; Hatzi K; Vu LP; Zhao X; Zatorska D; Taldone T; Smith-Jones P; Alpaugh M; Gross SS; Pillarsetty N; Ku T; Lewis JS; Larson SM; Levine R; Erdjument-Bromage H; Guzman ML; Nimer SD; Melnick A; Neckers L; Chiosis G
    Nat Chem Biol; 2011 Sep; 7(11):818-26. PubMed ID: 21946277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hsp90 inhibition aggravates adriamycin-induced podocyte injury through intrinsic apoptosis pathway.
    Dong J; Jiang Z; Ma G
    Exp Cell Res; 2020 May; 390(2):111928. PubMed ID: 32156599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.